Abuse-resistant opioid maker hires pharma veteran as CEO, raises $14 million
A drugmaker specializing in extended release, abuse-resistant drug delivery for opioids has raised more than $14 million in series B financing to advance its lead products through clinical trials. It has also hired a pharmaceutical veteran as its CEO. Bob Radie has joined Malvern, Pennsylvania-based Egalet as president and CEO. Radie has nearly 30 years […]